ASP Isotopes Inc. to Post FY2024 Earnings of ($0.11) Per Share, HC Wainwright Forecasts (NASDAQ:ASPI)

ASP Isotopes Inc. (NASDAQ:ASPI) – Research analysts at HC Wainwright cut their FY2024 EPS estimates for shares of ASP Isotopes in a note issued to investors on Wednesday, April 17th. HC Wainwright analyst H. Ihle now anticipates that the company will earn ($0.11) per share for the year, down from their previous forecast of $0.07. HC Wainwright has a “Buy” rating and a $5.50 price objective on the stock. The consensus estimate for ASP Isotopes’ current full-year earnings is $0.07 per share.

ASP Isotopes Trading Up 0.3 %

Shares of ASPI opened at $3.10 on Friday. The stock has a market capitalization of $151.65 million, a P/E ratio of -6.33 and a beta of 5.03. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $3.67 and a two-hundred day simple moving average of $2.40. ASP Isotopes has a twelve month low of $0.28 and a twelve month high of $4.97.

Insider Buying and Selling at ASP Isotopes

In other news, Director Robert John Andrew Ryan purchased 15,596 shares of the company’s stock in a transaction on Monday, January 29th. The stock was acquired at an average price of $2.35 per share, with a total value of $36,650.60. Following the transaction, the director now directly owns 537,055 shares of the company’s stock, valued at approximately $1,262,079.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 26.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ASP Isotopes

Several institutional investors and hedge funds have recently modified their holdings of ASPI. Armistice Capital LLC purchased a new position in ASP Isotopes during the 1st quarter valued at about $2,702,000. Renaissance Technologies LLC purchased a new position in ASP Isotopes during the 2nd quarter valued at about $272,000. GSA Capital Partners LLP purchased a new position in ASP Isotopes during the 4th quarter valued at about $608,000. Vanguard Group Inc. increased its stake in ASP Isotopes by 761.7% during the 4th quarter. Vanguard Group Inc. now owns 176,314 shares of the company’s stock valued at $316,000 after purchasing an additional 155,853 shares in the last quarter. Finally, Rathbones Group PLC bought a new stake in ASP Isotopes during the 4th quarter valued at about $272,000. 16.80% of the stock is owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.